New therapeutic options for immune thrombocytopenia

Netherlands Journal of Medicine

Volumn 69, Issue 11, 2011, Pages 480-485

  Schipperus, M ^a   Fijnheer, R ^b  

^a Department of Hematology ^*  (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Corticosteroids; Eltrombopag; Immune thrombocytopenic purpura; Intravenous immunoglobulin; Rituximab; Romiplostim; Splenectomy; Treatment

Indexed keywords

AKR 01; AMIFOSTINE; AS 1670542; CORTICOSTEROID; ELTROMBOPAG; FOSTAMATINIB; HEMOSTATIC AGENT; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

CELL SURVIVAL; CONTUSION; DISEASE REGISTRY; DIZZINESS; DRUG TARGETING; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; HYPOCALCEMIA; INCIDENCE; MEGAKARYOCYTE; NAUSEA; NETHERLANDS; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

BENZOIC ACIDS; BLOOD PLATELETS; HUMANS; HYDRAZINES; PRACTICE GUIDELINES AS TOPIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 83755183676     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965;124(2):499-542.
2. Heyns AP, Badenhorst PN, Lotter MG, Pieters H, Wessels P, Kotze HF. Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ. Blood. 1986;67(1):86-92.
3. Vainchenker W, Deschamps JF, Bastin JM, Guichard J, Titeux M, Breton-Gorius J, et al. Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood. 1982;59(3):514-21.
4. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-9.
5. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40.
6. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93.
7. Schipperus MR, Koene H, Zwaginga JJ, te Boekhorst PAW, Vreugdenhil G, Pruijt JFM, et al. Dutch guideline for the diagnosis and treatment of immune thrombocytopenia in adults. Nederlands Tijdschrift voor Hematologie 2010;7(10):59-68.
8. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-207.
9. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909-13.
10. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106(7):2244-51.
11. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49(8):664-6.
12. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol. 2010;150(1):9-20.
13. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377-83.
14. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008.
15. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
16. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica. 2008;93(1):98-103.
17. Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23-9.
18. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369(6481):568-71.
19. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607-16.
20. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett. 1995;374(1):48-52.
21. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001;97(1):139-46.
22. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241-8.
23. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs. 2008;68(7):901-12.
24. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25(2):52-60.
25. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
26. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161-71.
27. Amgen. Nplate (romiplostim) Summary of Product Characteristics. Accessed online 2011.
28. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739-41.
29. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237-47.
30. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393-402.
31. Chouhan JD, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy. 2010;30(7):666-83.
32. GlaxoSmithKleine. Revolade (eltrombopag) Summary of Product Characteristics. Accessed online 2011.
33. Van Meerten T, Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med. 2009;67(7):251- 9.
34. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755-62.
35. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-95.
36. Li Z, Mou W, Lu G, Cao J, He X, Pan X, Xu K. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93(1):91-8.
37. Colovic M, Suvajdzic N, Colovic N, Tomin D, Vidovic A, Palibrk V. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22(2):153-6.
38. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51(2):278-98.
39. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81(1):19-25.
40. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007;12(6):738-47.
41. Santini V, Giles FJ. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999;84(11):1035-42.
42. Fan H, Zhu HL, Li SX, Lu XC, Zhai B, Guo B, et al. Efficacy of amifostine in treating patients with idiopathic thrombocytopenia purpura. Cell Biochem Biophys. 2011;59(1):7-12.
43. Fan H, Zhu HL, Li SX, Lu XC, Yang Y, Yao SQ. [Therapy of 17 cases of idiopathic thrombocytopenia purpura by amifostine]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(1):192-6.
44. Abe M, Suzuki K, Sakata C, Sugasawa K, Hirayama F, Koga Y, et al. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist. Eur J Pharmacol. 2011;650(1):58-63.
45. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113(14):3154-60.